Indications
Mepsevii is indicated for the treatment of non-neurological manifestations of Mucopolysaccharidosis VII (MPS VII; Sly syndrome).
Composition
- Active substance
- vestronidase alfa
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Mepsevii
- Active substance
- vestronidase alfa
- ATC code
- A16AB18
- Therapeutic area
- Mucopolysaccharidosis VII
- Marketing authorisation holder
- Ultragenyx Germany GmbH
- Status
- Authorised
- EU authorisation
- 23 Aug 2018